Zobrazeno 1 - 8
of 8
pro vyhledávání: ''
Autor:
Dario Nieri, Maria Adelaide Roggi, Alessandro Celi, Barbara Vagaggini, Pierluigi Paggiaro, Giulia Parri
Publikováno v:
Expert Review of Respiratory Medicine. 12:997-1005
Introduction: Triple therapy with two bronchodilators (LABA plus LAMA) and an inhaled corticosteroid (ICS) is recommended for patients suffering from severe chronic obstructive pulmonary di...
Autor:
Luke Howard
Publikováno v:
Expert Review of Respiratory Medicine. 12:387-402
Acute pulmonary embolism (PE) is a relatively common cardiopulmonary emergency that is a major cause of hospitalization and morbidity and is the primary cause of mortality associated with venous thromboembolism (VTE). During the last decade, one of t
Publikováno v:
Expert Review of Respiratory Medicine. 11:763-778
Introduction: Many trials have been published comparing inhaled corticosteroid (ICS) treatments in asthma. However, mixed results necessitate the summarization of available evidence to aid in decision-making. Areas covered: This systematic review eva
Publikováno v:
Expert Review of Respiratory Medicine. 11:333-341
© 2017 Informa UK Limited, trading as Taylor & Francis Group. Introduction: To evaluate systematically randomised clinical trials investigating non-opioid medications for the management and treatment of chronic breathlessness. Areas covered: The evi
Autor:
Dindial Ramotar
Publikováno v:
Expert Review of Respiratory Medicine
article-version (VoR) Version of Record
article-version (VoR) Version of Record
Over the past two decades, we have successfully used old drugs such as the antibiotic and anticancer drug bleomycin to determine how cancer cells confer resistance to this agent. Using state-of-art...
Publikováno v:
Expert Review of Respiratory Medicine. 10:1069-1078
Fluticasone furoate (FF) is a novel inhaled corticosteroid (ICS). Vilanterol trifenate (VI) is a new inhaled, selective, long - acting β2 adrenergic agonist (LABA). It is now also marketed as a novel once daily combined ICS/LABA indicated for treatm
Autor:
R. Godoy Mayoral, F.J. Agustín Martínez, J. Cruz Ruiz, M Genovés Crespo, F.J. Callejas González, A J Martínez García, P J Tárraga López
Publikováno v:
Expert Review of Respiratory Medicine. 10:1023-1033
Chronic obstructive pulmonary disease (COPD) is a respiratory problem with the highest prevalence and strongest socio-economic impact in the world and whose morbimortality keeps increasing. Treating this disease is a challenge in the field of pneumol
Autor:
Kamal Sharma
Publikováno v:
Expert Review of Respiratory Medicine. 10:1-3
The endothelin (ET), nitric oxide (NO) and prostacyclin (PGI2) pathways are involved in pulmonary arterial hypertension (PAH) pathogenesis. While ET and NO are targeted early in the disease process, limitations of current pharmacotherapies that targe